Allen Stark
Psychiatry · Lake Oswego, ORNPI 1427125806
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Vanda Pharmaceuticals Inc. at 26.6% of the total. Reporting peaked in 2021 at $865 and has fallen 74.1% since, to $224 in 2023. Among psychiatry clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$781
- AbbVie$520
- Otsuka America Pharmaceutical, Inc.$429
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$335
- Teva Pharmaceuticals USA, Inc.$271
- Takeda Pharmaceuticals U.S.A., Inc.$171
- plus $426 from 9 others
What the payments were for
- Food & beverage$2,925100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 30 | $781 |
| AbbVie(2 entities) | 41 | $520 |
| Otsuka America Pharmaceutical, Inc. | 21 | $429 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $335 |
| Teva Pharmaceuticals USA, Inc. | 14 | $271 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $171 |
| Lundbeck LLC | 6 | $104 |
| Idorsia Pharmaceuticals US Inc | 3 | $70 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Alkermes, Inc. | 3 | $49 |
| Ironshore Pharmaceuticals Inc. | 3 | $47 |
| Eisai Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $36 |
| Corium, LLC | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $12 |
How this compares
$2,932 in reported general payments places this provider in the 95th percentile of 366 psychiatry providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $1,160 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $851 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $607 |
| Bupropion XlBupropion Hcl | 19 | $542 |
| Trazodone Hcl | 36 | $484 |
| Duloxetine Hcl | 13 | $314 |
| Zaleplon | 15 | $104 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Lake Oswego
- Erik VanderlipLake Oswego$6K
- Malika BurmanLake Oswego$359
- Andrew WilliamsBeaverton$84K
- Jacqueline AmatoMedford$27K
- Alisha MorelandPortland$20K
- Leigh Anne BresslerPortland$15K
- John LipkinEugene$15K
- Alfred LewyPortland$9K
- Hernan SchmidtEugene$8K
- Anca Maria BejenaruPortland$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.